Know Cancer

forgot password

Exploring the Potential of Dual Kinase JAK 1/2 Inhibitor Ruxolitinib (INC424) With Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis

Phase 2
18 Years
70 Years
Open (Enrolling)
Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis

Thank you

Trial Information

Exploring the Potential of Dual Kinase JAK 1/2 Inhibitor Ruxolitinib (INC424) With Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis

A two- stage Simon Phase II study will be conducted in each of two groups of patients:
related and unrelated donor transplants. In each donor transplant group, the first stage of
this design will include 11 patients evaluated for death or graft failure by 100 days
post-transplant. In each stratum, we will enroll additional patients (up to 20%) of stratum
total to take into account exclusions due to donor failure (such as donor deemed unsuitable
for stem cell donation due to medical or other reasons) only. Those patients who have
toxicities related to Ruxolitinib and not been able to reach HCT due to these toxicities
will be included in the estimation of overall failure rates. Only those patients who are
excluded based on donor related issues without any regimen related complications will be
excluded from the estimation of failure rates. However, all data on these patients will be

Inclusion Criteria:

- Documented diagnosis of primary myelofibrosis according to WHO criteria or post PV
myelofibrosis or post ET myelofibrosis as per IWG-MRT criteria

- Age 18-70 years

- Intermediate-2/ high-risk disease as per Dynamic IPSS (DIPSS) criteria OR
Intermediate-1 risk disease with one of the following additional unfavorable features
known to impact the survival adversely

1. Red cell transfusion dependency

2. Unfavorable Karyotype

3. Platelet count <100 x 109/l

- Blasts in the PB and BM <20% prior to study enrollment

- Availability of a suitable matched related (6/6 or 5/6) or unrelated donor (10/10 or
9/10 antigen or allele matched).

- Able to give informed written consent

- ECOG Performance status of 0-2.

- Life expectancy >3 months

- Off all MF-directed therapy including investigational agents for at least 2 weeks
prior to study enrollment and recovered from all toxicities*

- Adequate organ function

- Adequate renal function - creatinine <1.5 x IULN

- Adequate hepatic function - AST/ALT <2.5 x IULN, Total Bilirubin <1.5 x IULN

- Adequate hematopoietic function - Platelet ≥50 x 109/l and ANC ≥1.0 x 109/l

- LVEF >40% (MUGA or echocardiogram) Normal per Institutional standard

- Adequate pulmonary function with DLCO >50%

- A patient who has been on stable dose of Ruxolitinib and has received
ruxolitinib ≤6 months prior to the study entry will be considered
potentially eligible for the study with the caveat that there is no
evidence of loss of response (>5cm increase in spleen size from the nadir).

Exclusion Criteria:

- Any previous JAK2 inhibitor treatment prior to study enrollment, with the exception
of Ruxolitinib

- Hypersensitivity to JAK inhibitor

- Clinical or laboratory evidence of cirrhosis

- Prior allogeneic transplant for any hematopoietic disorder

- >20% blast in the PB or BM prior to HCT or had leukemic transformation (>20% blasts
in PB or BM any time prior to HCT)

- Syngeneic donor

- Cord Blood transplant

- Active uncontrolled infection

- H/o another malignancy within 5-years of date of HCT except h/o basal cell or
squamous cell carcinoma of skin or PV or ET

- Known HIV positive

- Pregnancy at the time of BMT

- Any other concurrent illness which in investigator's opinion puts the patient at
excessive risk of treatment related toxicities

- Unable to give informed consent

- Active infection with hepatitis A,B or C virus

- Subjects who require therapy with a strong CYP3A4 inhibitor prior to enrollment to
this study

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Assessment of 100-day survival without graft failure

Outcome Description:

To determine the feasibility of combining Ruxolitinib (INC424) with a RIC regimen likely to produce success post transplantation, success being defined as patient being alive, and without graft failure at day 100-post allogeneic stem cell transplantation (in patients who receive (a) related donor transplant and in those who receive (b) an unrelated donor transplant.

Outcome Time Frame:

Day 100-post allogeneic stem cell transplantation

Safety Issue:


Principal Investigator

John Mascarenhas, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Icahn School of Medicine at Mount Sinai


United States: Food and Drug Administration

Study ID:

GCO 12-1809



Start Date:

February 2013

Completion Date:

February 2021

Related Keywords:

  • Primary Myelofibrosis
  • Post Polycythemia Vera Myelofibrosis
  • Post Essential Thrombocythemia Myelofibrosis
  • Myelofibrosis
  • Stem cell transplant
  • Ruxolitinib
  • Primary Myelofibrosis
  • Polycythemia
  • Polycythemia Vera
  • Thrombocythemia, Essential
  • Thrombocytosis



University of Illinois at Chicago Chicago, Illinois  60612
University of Utah Salt Lake City, Utah  
Ohio State University Columbus, Ohio  43210
Mayo Clinic - Arizona Scottsdale, Arizona  85259
Emory Hospital Atlanta, Georgia  30322
Icahn School of Medicine at Mount Sinai New York, New York  10029
Weill CornellMedical College New York, New York  10065